Mythic Therapeutics Presents Trial in Progress Poster on Investigational cMET-Targeting Antibody-Drug Conjugate (ADC) MYTX-011 at American Society of Clinical Oncology (ASCO) Annual Meeting
The Phase 1 KisMET-01 clinical trial enrolls patients with locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC) Waltham, Mass.,
Mythic Therapeutics Announces First Subject Dosed in Phase 1 KisMET-01 Clinical Trial of cMET-Targeting Antibody-Drug Conjugate (ADC) MYTX-011 for the Treatment of Non-Small Cell Lung Cancer (NSCLC)
MYTX-011 incorporates Mythic’s FateControl™ technology, which holds the potential to dramatically improve ADC efficacy, thereby expanding the number of NSCLC
Gilles Gallant, BPharm, PhD, FOPQ, Receives the George R. Pettit Individual Input to the Field Award for 2022
Waltham, Mass., September 27, 2022 (BUSINESS WIRE) -- Mythic Therapeutics, a biotechnology company focused on the development of antibody-drug conjugate-based
Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer
Waltham, Mass., August 23 2022 (BUSINESS WIRE) -- Mythic Therapeutics, a biotechnology company focused on the development of antibody-drug conjugate-based
Mythic Therapeutics Launches with New Approach to Improving Antibody Drug Conjugate Performance, Backed by $103 Million in Series B Financing
Mythic’s FateControl™ technology holds the potential to dramatically improve the therapeutic index of ADCs, independent of the linker and payload Series